Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 473-820-3 | CAS number: -
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
A literature-based toxicokinetic assessment was carried out.
Key value for chemical safety assessment
Additional information
The data presented in this dossier only allows a qualitative assessment of the toxicokinetic behaviour of the substance for registration. The data was awarded a reliability score of 4 in accordance with the criteria for assessing data quality set forth by Klimisch et al. (1997). However, a couple of significant conclusions can be made.
Hyperform™ HPN-20E has a molecular weight of 210 g/mol. It is a poorly soluble solid (solubility 296 mg/L), with over 87 % of the particles being >100 µm in size. The melting point is > 360 °C and the substance has a very low vapour pressure. The logPow is -2.56. The substance appears stable in solution at pH 4, 7 and 9. The substance is essentially non-toxic.
Absorption
The substance is poorly soluble in water and even less soluble in lipids. Thus it is unlikely to be absorbed orally or dermally. Although a poorly soluble particulate, the particle size is such that very little is likely to be inhaled and retained.
Distribution
The substance is essentially unlikely to be distributed and, if administered parenterally, is likely to remain at the site of administration.
Metabolism
Given the solubility profile of the material it is unlikely to become available for metabolism.
Excretion
Given the solubility profile of the substance, it is not likely to be available for excretion. If particles lodge in the alveolus following inhalation, they will be dealt with largely as insoluble particulates, and if the substance is administered orally it is likely to appear in faeces unabsorbed.
Conclusion
Given the solubility profile and particle size, the substance is unlikely to be absorbed orally or dermally, and is unlikely to be inhaled and retained. Given the solubility of the material, it is also unlikely to become available for metabolism or excretion. If particles lodge in the alveolus following inhalation, they will be dealt with largely as insoluble particulates, and if the substance is administered orally it is likely to appear in faeces unabsorbed.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
